Clinical

The general stigma and bias circulating obesity hinders the ability to improve the patient’s health, explained Ted Kyle, RPh, MBA, principal at ConscienHealth. With number of individuals with obesity, patients, physicians, and payers can’t afford to think of obesity as a purely cosmetic condition.

Within 4 months of the last reported incident, Juno Therapeutics has again halted the phase 2 “Rocket” trial of JCAR015 in patients with relapsed or refractory B cell acute lymphoblastic leukemia (ALL).

Here's a glimpse into what The American Journal of Managed Care’s 5th annual Patient-Centered Oncology Care® meeting had in store for its attendees.

This week, the top managed care stories included the FDA's approval of rival combination therapies for type 2 diabetes, the American Medical Association issued mHealth guidelines, and a study found the dementia rate declining.

What we're reading, November 23, 2016: Alaska has a novel plan to hold down insurance premiums; MedPAC's executive director discusses continuation of value efforts; and new findings regarding microcephaly in Zika-infected babies.

What we're reading, November 22, 2016: Virginia declares opioid addiction a public health emergency; House calls for a pause of ongoing Obamacare lawsuit; and Anthem-Cigna antitrust trial begins.

A prospective trial that reached out to patients with cirrhosis to undergo an ultrasound screen found that the outreach effort doubled the percentage of patients who were screened for hepatocellular carcinoma.

Clinicians can sometimes focus only on a patient’s medical needs, but listening to the patient’s own goals and priorities often reveals social drivers of health that must be addressed, said Renee Murray, associate clinical director of Care Management Initiatives at Camden Coalition.

Many payers are incorporating Fitbit technology into healthcare plans as part of both prevention and clinical treatment programs, hoping that it can help members become healthier and more active, according to Ben Sommers, MBA, vice president of North America Business Development at Fitbit Wellness.

A study published by researchers from the Fred Hutchinson Cancer Research Center in Seattle has found that admission to the intensive care unit reduced survival and increased the cost of care among patients undergoing treatment for acute myeloid leukemia.

The authors developed and validated a survey instrument to assess primary care providers’ and pharmacists’ experiences, attitudes, and beliefs regarding medication discontinuation.

A study conducted in Canada to estimate the prevalence of psychotropic and opioid medication use by older women diagnosed with breast cancer found a significant increase in use, especially during the active treatment phase.

Gerd Burmester, MD, of Charité — Universitätsmedizin Berlin, discussed the results of a randomized, double-blind monotherapy study comparing the safety and efficacy of sarilumab with adalimumab in patients who cannot tolerate methotrexate.

A hospital in China has made history by injecting a patient with lung cancer with revolutionary, yet controversial, CRISPR-Cas9—edited T cells. The first patient was injected on October 28.

Amgen and Allergan have announced that they have submitted a Biologics License Application (BLA) for ABP 215, a biosimilar to bevacizumab (Avastin).

During a session at the Annual Meeting of the American College of Rheumatology, John D. Isaacs, MD, PhD, FRCP, not only reviewed regulatory perspectives as biosimilars enter the market, but conveyed the importance of crafting antibodies to our own purposes.

A new study conducted at the Massachusetts General Hospital evaluated the impact of intraoperative radiotherapy (IORT), along with induction chemotherapy and chemo-radiotherapy, in patients with advanced disease, and observed hints of success.

David Hafler, MD, chairman of the Department of Neurology at the Yale School of Medicine, spoke of exciting times in the field of genome-wide association study-specifically speaking to neurology, genetics, the environment, and the autoimmune response.

A prospective trial among breast cancer patients enrolled in The Pathways Study has found that higher levels of vitamin D can lower the risk of breast cancer morbidity and mortality.

Overall, both case management (CM) and disease management (DM) are vital to reduce healthcare costs by helping beneficiaries control their disease and prevent excessive utilization. However, there are differences in their approach.

Using precision medicine to implement clinical decisions can help healthcare providers achieve the triple aim, said Leonard M. Fromer, MD, FAAFP, executive medical director of the Group Practice Forum.

A study conducted in Australia has concluded that a person’s inherited risk factors for melanoma should be considered when developing self-examination and surveillance programs.

What we're reading, November 11, 2016: Medicare premium increases lower than expected for high earners; HHS' Office of Inspector General will increase pharmaceutical oversight; and a study on the safety of mail-order abortion pills.

The FDA today granted approval to the programmed death ligand-1 inhibitor, nivolumab (Opdivo), for treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN), following platinum-based treatment.

Get Smart About Antibiotics Week raises awareness about the threat of antibiotic resistance and emphasizes the importance of appropriate antibiotic use.